Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)
The purpose of this Notice of Amendment is to notify about the additions of amifampridine, cedazuridine (when used in combination with another drug), etomidate, fedratinib, lefamulin, obiltoxaximab, polatuzumab vedotin, ripretinib, satralizumab and sonidegib to the Prescription Drug List (PDL) for human and/or veterinary use.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)HTMLEnglish publication HTML
-
Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)HTMLFrench publication HTML
Similar records